Principal Financial Group Inc. Buys 63,581 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Principal Financial Group Inc. boosted its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 14.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 513,618 shares of the company's stock after acquiring an additional 63,581 shares during the quarter. Principal Financial Group Inc. owned approximately 0.60% of Pediatrix Medical Group worth $5,953,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of Pediatrix Medical Group by 1.4% during the 3rd quarter. State Street Corp now owns 3,540,791 shares of the company's stock worth $41,038,000 after acquiring an additional 50,597 shares in the last quarter. Aristeia Capital L.L.C. bought a new stake in Pediatrix Medical Group during the second quarter worth approximately $687,000. Barclays PLC boosted its position in Pediatrix Medical Group by 302.9% during the third quarter. Barclays PLC now owns 142,087 shares of the company's stock worth $1,646,000 after purchasing an additional 106,817 shares during the period. Rubric Capital Management LP raised its position in shares of Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company's stock valued at $61,532,000 after purchasing an additional 7,241,400 shares during the period. Finally, Weiss Asset Management LP raised its position in shares of Pediatrix Medical Group by 50.5% in the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company's stock valued at $10,580,000 after purchasing an additional 306,143 shares during the period. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Stock Performance

MD stock traded down $0.09 during midday trading on Thursday, hitting $13.03. The stock had a trading volume of 475,848 shares, compared to its average volume of 857,979. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. The stock has a 50-day simple moving average of $14.34 and a 200 day simple moving average of $11.36. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -4.26, a P/E/G ratio of 2.00 and a beta of 1.57.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm's revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm earned $0.29 EPS. As a group, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on MD shares. Jefferies Financial Group raised their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a "hold" rating in a research report on Monday, November 4th. Macquarie began coverage on Pediatrix Medical Group in a report on Monday, December 16th. They issued an "outperform" rating and a $18.00 target price on the stock. Truist Financial upped their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Finally, UBS Group raised their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Pediatrix Medical Group currently has a consensus rating of "Hold" and an average price target of $16.42.

Insider Buying and Selling at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the firm's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.00% of the company's stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.